Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | FLT1 | P17948 | 2/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | FADS1 | O60427 | 1/20 | 0.54 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611478 | 1.00 | EGFR (0.69) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL22946710 | 0.90 | EGFR (0.62) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL3035598 | 0.82 | ROCK2 (0.60) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL5461595 | 0.81 | EGFR (1.00) | EGFRFLT1FADS1PIP4K2C | |
| SCHEMBL30611453 | 0.81 | MKNK1 (0.69) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL4035154 | 0.79 | MKNK1 (0.55) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL13220437 | 0.78 | ROCK2 (0.54) | EGFRFLT1MKNK1ROCK2ROCK1 | |
| SCHEMBL13434870 | 0.78 | MKNK1 (0.60) | EGFRFLT1MKNK1RETCDC7 | |
| SCHEMBL2835747 | 0.78 | EGFR (0.74) | EGFRFLT1MKNK1RETROCK2 | |
| SCHEMBL29516907 | 0.78 | EGFR (0.74) | EGFRFLT1MKNK1RETROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| WO-2007115822-A1 | THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | EGFR 4110/4885FLT1 3883/4885MKNK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.